Thus, a common strategy aimed at modulating tumor microenvironment rich in FAP+ fibroblasts, inhibiting PD-L1 expression, increasing tumor T-cell infiltration and upregulating HLA-I in tumors without LOH or mutations/deletions in HLA genes, might provide a new framework for rational combination immunotherapy. The gene discussed is CD274; the disease is neoplasm.